Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
200 bill MA contingency.
If only $500,000, that's $2 million in earnings for 2023, or a current P/E of 2. I won't sell at a forward P/E much lower than 25.
Not sure what a surprisingly good would mean, but this is my Q4 estimate: "2023 saw inpatient admissions increase by over 75% compared to 2022" (Jan 16 update) Along with other service increases, that translates to Q4 revenues of $5.5-7.5 million. Cost-based CAH reimbursements give us some certainty that the cost of revenues improved with new Myrtle Recovery revenues coming in to around 40-45%, but for the minimum estimate, assume it remained at the 50% reported for Q3. Other expenses being roughly equal or maybe increasing slightly, Q4 earnings were $1-2.5 million.
Wrong again, GeekOfSkidRow. https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173906438
Yep. RNVA holds a strong equity position and also made a note to INQR that came due on 12/31 in the amount of $2.5 million. We should hear news on repayment next. Good guess anyway.
.0025/.025/.25 will work for me.
OMG, it doesn't work that way. Those are reputable stock research services that follow reputable analysts. Then there is you.
I passed on some info. You didn't understand it, but you trashed it anyway. It's sort of obvious.
You are the one whinning because I trust reputable sources over you. Sensitive? No, I've just lost my patience for disingenuous BS.
Probably the same analyst followed by other reputable stock research services, the one on MarketWatch now covering RNVA for example. If it mattered to you who the particular analyst is, you would track it down yourself. Of course it doesn't matter to you. You just trash whatever info is posted, no matter the source. Congrats Fats. You made my point. Whoever it is, the analyst is more qualified to comment on RNVA than you are.
I didn't imply anything. An analyst the WSJ follows just began covering RNVA this month. I consider the WSJ a good source and trust that the analysts it follows are qualified. It is notable because .0001s are not normal fare for a WSJ analyst to cover. The analyst didn't just pick RNVA out at random and begin covering it. There had to be a reason or reasons to initiate coverage at this time.
My sense is we'll see some heavy volume for a change ahead of that report, maybe some price action too. New eyes on RNVA in important places, bringing new long holders and accumulation. Just my sense.
Not easily seen. You have to the study the earnings reports going back a few quarters, read the SEC filings and do whatever research you need to do to understand the filings, and examine the information provided in company updates. Then you have to apply all that to make your best estimate of revenue and earnings growth, as well as the accomanying improvements in the balance sheet, P/L, and P/E. It doesn't hurt to understand the industry too. Do the DD and it's easy to see.
RNVA is going to show you some f-ing woke. The last two links I posted here were from Forbes and the Wall Street Journal. That's some really woke reading. Caught me.
With you. We're about to make a little money here.
I haven't lost a dime on RNVA. That's hardly desperate. FO loser.
You lost your ass because you bought RNVA when it was losing money and, therefore, diluting. You are THE loser of losers.
Another lie. Nobody trusts a word you type, loser.
Gut says RNVA March madness just around the corner.
WSJ analyst or FatStrat's post, which one should I pay attention to? hmmmmm
Balance sheet improving as we speak. $1 million per quarter in 2023 debt reduction. More "restructuring of debt and other securities" in progress. I once did business plans for clients of a business brokerage. For RNVA's current P/E below 2, the better buyers on the client list would eat that balance sheet for lunch.
Jay, you need to think about this. Why does an analyst the WSJ follows happen to begin covering RNVA just this month? That's the WSJ posting an analyst's rating on a ,0001 stock. That is highly unusual. When we see some price action, and soon, that analyst will upgrade the rating from hold to buy. Mark my word. There is way too much penny anty, low rent, non-SEC compliant, please more PR and more rumors kind of thinking on this board. The earnings reports are stering. It's not magic. Get real people. RNVA will break out of the 000s because it's worth it. It's just that simple.
https://www.wsj.com/market-data/quotes/RNVA/research-ratings
I don't know exactly, just ran across it yesterday. Will be watching that rating though. I have argued that macro factors, as well as micro, favor RNVA. The Forbes and the WSJ links support my argument.
https://www.wsj.com/market-data/quotes/RNVA/research-ratings
https://www.forbes.com/sites/gebai/2024/01/21/rural-urban-healthcare-access-gap-its-all-about-the-fixed-costs/?sh=75d03b146288
Or maybe it just needs a few investors.
All I know is last month Forbes editors thought readers(investors) might be interested in how CAH reimbursements work and this month a WSJ analyst decided it might be a good idea to cover RNVA in particular. I'll bet the rating is raised to "buy" shortly after, if not before, the next earnings report.
I don't know which analyst, will try to find out, but how many .0001s are covered by any Wall Street Journal analyst? The Forbes article doesn't mention RNVA, but how many listed companies have a CAH as their core business? Only a fraction of other listed health care companies' revenues are CAH driven.
Wake up call!!! An analyst the Wall Street Journal follows just began covering RNVA this month! Initiated as a hold. Proof: https://www.wsj.com/market-data/quotes/RNVA/research-ratings
And remember this Forbes article last month? https://www.forbes.com/sites/gebai/2024/01/21/rural-urban-healthcare-access-gap-its-all-about-the-fixed-costs/?sh=75d03b146288
Who doesn't know what time it is?
My first 000 breakout netted me $35k on $1000. I spotted some value the market was overlooking. With RNVA, the value is not so easy to overlook. It's all in the SEC filings and updates.
In my 30 years of OTC trading, I have never been more certain a stock will break out of the 000s. It's already worth more than that by any valuation measure.
Good point.. My numbers don't include the interest savings but there would have been some interest savings accumulated from the $2.9 million debt reduction plus maybe a month or two of interest savings on the note restructured in late October.
Let's say the cost of revenues didn't improve in Q4, though we know it would have under the CAH reimusement system, we still know that RNVA turned over $20 million in 2023 revenue with a profit of at least $2 million, bare minimum. That's a P/E of 2 on a 40 billion share OS. Enough with all the bedwetting over share structure. People just need to buy the damned stock. It's underpriced to the point of being downright ridiculously cheap.
"2023 saw inpatient admissions increase by over 75% compared to 2022" (Jan 16 update) Along with other service increases, that translates to Q4 revenues of $5.5-7.5 million. Cost-based CAH reimbursements give us some certainty that the cost of revenues was about 40-45%. Other expenses being roughly equal or maybe increasing slightly, Q4 earnings were $1-2.5 million.
No kidding. We're looking at what, $2-3 million in 2023 earnings on $20-23 million in revenues. That's a fairly minimal projection based on all the filings and updates. Sometimes I wonder if anyone reads earnings reports anymore.
With a current P/E under 2, the share structure must not 'suck" that much.
Last trading day of the week before a Monday holiday. Tuesday opening might get really interesting.
Your lack of information is not my problem. Learn how to read earnings reports.
18 months of dynamic revenue and earnings growth with $1 million per quarter in debt reduction in 2023. They didn't read earnings reports then. They don't read them now. Probably wouldn't understand them if they did.
Interesting how that question comes from the one who is doing one post after another..., excessively or obsessively, we never know which.
Thanks for the update.